Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Optimizing Anthracycline Therapy for Node Positive Breast Cancer

Optimizing Anthracycline Therapy for Node Positive Breast Cancer Anthracyclines are among the most active cytotoxic drugs against breast cancer and are currently considered to be the standard agents for the adjuvant treatment of patients with node positive breast cancer. Nevertheless, the benefits attained by the use of the more active anthracycline schedules must be balanced against increased short- and long-term toxicity, and treatment options must be individualized for each patient. The authors review the available data regarding anthracycline efficacy and toxicity in the early breast cancer setting, the controversial issues still pending, and the potential directions for future research. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Optimizing Anthracycline Therapy for Node Positive Breast Cancer

Loading next page...
 
/lp/springer-journals/optimizing-anthracycline-therapy-for-node-positive-breast-cancer-Qnx0G4d6g0
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201040-00003
Publisher site
See Article on Publisher Site

Abstract

Anthracyclines are among the most active cytotoxic drugs against breast cancer and are currently considered to be the standard agents for the adjuvant treatment of patients with node positive breast cancer. Nevertheless, the benefits attained by the use of the more active anthracycline schedules must be balanced against increased short- and long-term toxicity, and treatment options must be individualized for each patient. The authors review the available data regarding anthracycline efficacy and toxicity in the early breast cancer setting, the controversial issues still pending, and the potential directions for future research.

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

References